Voyager Therapeutics, Inc.
Company Stats
- Market Cap
- $165.1M
- as of Sep 30, 2026
- Shares Outstanding
- 61.6M
- Free Float
- 56.3%
Income Statement
- Revenue
- $40.4M
- Operating Income
- -$131.8M
- Net Income
- -$119.7M
- EBITDA
- -$127.8M
- Revenue Growth, 3Y
- -0.4%
- FCF Margin, 3Y Avg
- -109.4%
- FCF Margin, Worst Year
- -334.5%
Cash Flow
- Free Cash Flow
- -$135.1M
- FCF Yield
- -81.8%
- Owner FCF Yield
- -90.7%
Balance Sheet
- Cash & Equivalents
- $65.3M
Returns & Capital
- SBC, 3Y Avg
- $13.6M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $40.4M | -$135.1M | -334.5% |
| FY2024 | $80.0M | -$18.8M | -23.5% |
| FY2023 | $250.0M | $74.7M | 29.9% |
| FY2022 | $40.9M | -$15.0M | -36.7% |
| FY2021 | $37.4M | -$55.1M | -147.4% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 2, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back